Drugs / XELAGLIFAM
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04982705 | Jul 2021 → Nov 2022 | type 2 diabetes mellitus | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XELAGLIFAM | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314448 ↗ |
| Known as | IDG-16177 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04982705 ↗ |
| Modality | Small molecule | — CHEMBL5314448 ↗ |
| Route | Oral | “Subjects will receive a single oral dose of IMP.” NCT04982705 ↗ |